PCSK9 ... Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. [5] It is the 9th member of the proprotein convertase family of …

Feb 17, 2022 · What are PCSK9 inhibitors? PCSK9 inhibitors are a type of cholesterol-lowering drug. They reduce your low-density lipoprotein (LDL) cholesterol or “bad” cholesterol. This medication may …

Sep 9, 2025 · PCSK9 inhibitors are an injectable treatment for high LDL cholesterol that may provide a safe alternative for people who can’t take statins or who have genetic conditions that increase the risk...

Oct 2, 2025 · Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes.

Feb 25, 2024 · This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors.

Jan 8, 2024 · Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related ...

Nov 15, 2024 · PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. Right now, there are two FDA-approved medications: alirocumab (Praluent) and evolocumab (Repatha).

Aug 27, 2025 · Although all three drugs inhibit a protein called PCSK9 (proprotein convertase subtilisin kexin 9), they work by different mechanisms. Repatha and Praluent are monoclonal antibodies that …

Nov 20, 2015 · Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) plays an important role in cholesterol metabolism by regulating LDL receptor degradation. Shortly after its discovery in …

PCSK9 inhibitors (or PCSK9i) are a new type of medicine for lowering cholesterol in the blood. Discover how PCSK9 inhibitors work, who should take them and possible side effects.